+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Adverum Biotechnologies - logo

Adverum is a gene therapy company that innovate and produce medicines for rare and eye diseases that do not have many existing treatments. Adverum focuses on 7 key areas such as: wAMD, A1T Deficiency, HAE, FA, Severe allergy, Color vision deficiency, and XLRS. Adverum biotechnologies was founded in 2006, and it is headquartered in Menlo park, California. The company was previously known as Avalanche Technologies but changed its name to Adverum Biotechnologies in May 2016. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases.

From
Diabetic Retinopathy - Pipeline Review, H2 2020 - Product Thumbnail Image

Diabetic Retinopathy - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 358 pages
From
From
From
From
From
From
From
From
From
Wet Macular Degeneration - Pipeline Insight, 2020 - Product Thumbnail Image

Wet Macular Degeneration - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 pages
From
From
Diabetic Macular Edema - Pipeline Review, H2 2020 - Product Thumbnail Image

Diabetic Macular Edema - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 319 pages
From
From
Age Related Macular Degeneration - Pipeline Review, H1 2020 - Product Thumbnail Image

Age Related Macular Degeneration - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 864 pages
From
From
From
Loading Indicator
adroll